Aw Jeez.. Dr. Koots is a mealy mouthed Kon man. If anything comes of NR2F6 checkpoint inhibitors under the research of Regen, you can be sure the shareholders will be left out. Witness the parent company of RGBP, namely BMSN. Skybleu will be the next incarnation in this string of Koots Kompanies.